Target and Its Patented Drug(s)
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T73725 | Target Info | |||
| Target Name | CDC-like kinase 2 (CLK2) | ||||
| Synonyms | Dual specificity protein kinase CLK2 | ||||
| Target Type | Patented-recorded Target | ||||
| Gene Name | CLK2 | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Patent(s) and the Corresponding Patented Drug(s) | Top | ||||
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | |||||
| Patent ID | WO2009085226 | ||||
| Title | Inhibitors of Cdc2-Like Kinases (Clks) and Methods of Use Thereof. | ||||
| Abstract | Provided herein are compounds which are CDC2-Like Kinase (CLK) inhibiting compounds and methods of use thereof. The CLK-inhibiting compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, ocular disorders, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a Clk-inhibiting compound in combination with another therapeutic agent. | ||||
| Applicant(s) | Sirtris Pharmaceuticals, Inc | ||||
| Representative Drug(s) | D06MBI | Drug Info | N.A. | [1] | |
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.